Page last updated: 2024-12-05

ic 140

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

IC 140: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	8994
CHEMBL ID	1870347
MeSH ID	M0048084

Synonyms (33)

Synonym
phenol, ester with p-(carboxyamino) benzoic acid
n-[p-[bis(2-chloroethyl)amino]phenyl] p-carboxycarbanilate
nsc-130998
carbanilic acid, n-[p-[bis(2-chloroethyl)amino]phenyl] ester
phenol, ester with p-(carboxyamino)benzoic acid
benzoic acid, 4-[[[4-[bis(2-chloroethyl)amino]phenoxy]carbonyl]amino]-
nsc130998
benzoic acid, p-[[[4-[bis(2-chloroethyl)amino]phenoxy]carbonyl]amino]-
148-78-7
mls003389433 ,
ic 140
carbanilic acid, [4-[bis(2-chloroethyl)amino]phenyl] ester
i.c. 140
p-(n,n-di-2-chloroethylamino)phenyl n-(p-carboxyphenyl)carbamate
benzoic acid, 4-(((4-(bis(2-chloroethyl)amino)phenoxy)carbonyl)amino)-
carbanilic acid, p-carboxy-, 4-bis(2-chloroethylamino)phenyl ester
p-(n,n-di-2-chloroethyloamino)-phenyl-n-(p-carboxyphenyl)carbamate
carbanilic acid, p-carboxy-, n-(p-(bis(2-chloroethyl)amino)phenyl) ester
nsc 130998
brn 2823442
carbanilic acid, p-carboxy-, (4-(bis(2-chloroethyl)amino)phenyl)
n-(p-(bis(2-chloroethyl)amino)phenyl) p-carboxycarbanilate
4-(((4-(bis(2-chloroethyl)amino)phenoxy)carbonyl)amino)benzoic acid
4-[[4-[bis(2-chloroethyl)amino]phenoxy]carbonylamino]benzoic acid
smr002049086
cy2p0c893x ,
unii-cy2p0c893x
CHEMBL1870347
DTXSID80163864
4-(n,n,-bis-(2-chloroethyl)amino)phenyl-n-(p-carboxyphenyl)carbamate
ic-140
4-(n,n-bis(2-chloroethyl)amino)phenyl-n-(p-carboxyphenyl)carbamate
phenol, p-(bis(2-chloroethyl)amino)-, p-carboxycarbanilate (ester)

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Potency Measurements

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
GLS protein	Homo sapiens (human)	Potency	31.6228	0.3548	7.9355	39.8107	AID624170
TDP1 protein	Homo sapiens (human)	Potency	0.5708	0.0008	11.3822	44.6684	AID686978; AID686979
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (11)

Assay ID	Title	Year	Journal	Article
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	1 (20.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (20.00)	29.6817
2010's	2 (40.00)	24.3611
2020's	1 (20.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 39.02

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	39.02 (24.57)
Research Supply Index	1.95 (2.92)
Research Growth Index	4.14 (4.65)
Search Engine Demand Index	51.24 (26.88)
Search Engine Supply Index	2.00 (0.95)

This Compound (39.02)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	1 (20.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	4 (80.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
carbamates [no description available]	3.33	1	1	amino-acid anion

Condition	Relationship Strength	Studies	Trials
Innate Inflammatory Response [description not available]	2.05	1	0
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	2.05	1	0
Remission, Spontaneous A spontaneous diminution or abatement of a disease over time, without formal treatment.	3.33	1	1
Adenocarcinoma, Basal Cell [description not available]	3.33	1	1
Breast Cancer [description not available]	3.33	1	1
Leukocytopenia [description not available]	3.33	1	1
Cancer of Liver [description not available]	3.33	1	1
Cancer of Lung [description not available]	3.33	1	1
Diffuse Mixed Small and Large Cell Lymphoma [description not available]	3.33	1	1
Benign Neoplasms [description not available]	3.33	1	1
Cancer of Ovary [description not available]	3.33	1	1
Thrombopenia [description not available]	3.33	1	1
Adenocarcinoma A malignant epithelial tumor with a glandular organization.	3.33	1	1
Breast Neoplasms Tumors or cancer of the human BREAST.	3.33	1	1
Leukopenia A decrease in the number of LEUKOCYTES in a blood sample below the normal range (LEUKOCYTE COUNT less than 4000).	3.33	1	1
Liver Neoplasms Tumors or cancer of the LIVER.	3.33	1	1
Lung Neoplasms Tumors or cancer of the LUNG.	3.33	1	1
Lymphoma, Non-Hodgkin Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.	3.33	1	1
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	3.33	1	1
Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.	3.33	1	1
Thrombocytopenia A subnormal level of BLOOD PLATELETS.	3.33	1	1

chemdatabank.com